RefleXion’s precision radiotherapy offers 100% local tumour control

The radiotherapy technology controlled localised disease while triggering no adverse events (AEs) rated Grade 2 or higher.

RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors

RefleXion Medical, an external‑beam theranostic oncology company, today announced first results from the PREMIER Registry ...
Business Wire

RefleXion Raises $80 Million to Broaden Cancer Treatment Options

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced the close of an ...
Business Wire

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its ...
Physics World

RefleXion debuts PET-guided radiation therapy

What if you could take cancer’s natural activity in the human body and turn it back on itself? That’s the premise behind RefleXion, which made its debut at last week’s ASTRO Annual Meeting with a ...